10,822
Total Publications
801,107
Total Citations
Top Researchers
- Piotr Rutkowski 86,858 citations • 1758 papers
- George Kirov 84,307 citations • 525 papers
- Irmina Maria Michałek 82,189 citations • 113 papers
- Jolanta Lissowska 64,430 citations • 746 papers
- Susanna C. Larsson 42,303 citations • 955 papers
- Dariusz M. Kowalski 27,379 citations • 331 papers
- Jan Walewski 22,652 citations • 458 papers
- Wojciech Jurczak 20,786 citations • 646 papers
- Barbara Jarząb 20,425 citations • 468 papers
- Adam Płużański 16,980 citations • 117 papers
Most Cited Papers
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma 2015 • 8,073 citations
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 2017 • 5,345 citations
- Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation 2014 • 5,319 citations
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial 2016 • 4,738 citations
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer 2008 • 3,689 citations
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 2019 • 3,656 citations
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial 2019 • 3,281 citations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial 2012 • 2,955 citations
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer 2011 • 2,754 citations
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib 2014 • 2,631 citations